Divis Labs

It would be advisable to trade longs with trailing stop loss. Support for the index is seen at 15,800.

Realty stocks on the back of PAG taking a contra call on the sector and corporate earnings will be in focus today

Total income rose to Rs 1,997 crore in the first quarter as compared with Rs 1,748 crore in the June quarter

After hitting a new all-time high of Rs 997 earlier today, the stock of Cipla is all set to rally towards Rs 1,100

The short term trend is positive where the stock is trading above its 5-, 20- and 50-day EMA

Most metal stocks are trading at their record highs and showing no sign of slowing down

PNB plans to raise Rs 3,200 crore from share sale during the current quarter to enhance its capital base

Pidilite's stock is in a secular uptrend and has formed a bullish Harami candlestick pattern on the daily chart

Short covering was seen in the Divi's Lab Futures' where we have seen 1 per cent fall in the Open Interest with price rising by 3 per cent

The momentum indicator RSI has also breached the falling trend line and MACD provided a fresh buy crossover on the daily chart which hints of further positive momentum in Divis Labs

Till Nifty Pharma holds above the 11,180 mark, the bullish bias will prevail, charts suggest.

At 02:17 pm, Dr Reddy's Labs market cap stood at Rs 90,348 crore while that of Divi's Laboratories stood at Rs 89,119 crore, BSE data show

The stock of Divis Labs has witnessed some correction and has showed signs of bottoming out near 2140 levels. The RSI is showing a trend reversal from the oversold zone to signal a buy

One should refrain from creating any aggressive long position in Nifty at higher levels

Market Ahead, February 12: Top factors that could guide markets today

A total of 486 companies, including Divi's Laboratories, Dish TV, Ashok Leyland, and IRCTC, are scheduled to announce their earnings today

Godrej Consumer has picked up momentum with decent improvement in the volume to show a positive bias and imply further strength and potential to rise further in the coming days

Technical Calls by Gaurav Garg, Head of Research at CapitalVia Global Research Limited- Investment Advisor

BS ReporterHyderabad, 29 October: Active pharmaceutical ingredients(APIs) and drug intermediates maker Divis Laboratories Limited is creating additional capacities by spending as much as Rs 15 billion at its existing facilities in the next 15 months to more than make up for the delayed green-field project plans in Kakinada.The company said it would be investing Rs 6 billion each at its Unit-2 of Vizag SEZ in Andhra Pradesh and Unit-1 of its Nalgonda SEZ in Telangana to build additional capacities besides spending another Rs 3 billion for debottlenecking of the Unit-2 in Vizag. The work of the ongoing capacity expansion is expected to be completed by the end of calendar year 2019.The company currently operates four multi-purpose manufacturing facilities out of these two sites. The management said the brown-field expansion was taken up in order to cater to the increasing opportunities in generic and big pharma business. The company is engaged in the manufacturing of key ingredients ...

Street hopes for quick resolution, even as import alert impacts biz

The stock surges 20% to Rs 816 on BSE in intra-day trade